AIM ImmunoTech (NYSEAMERICAN:AIM) Announces Earnings Results

AIM ImmunoTech (NYSEAMERICAN:AIM) announced its earnings results on Friday. The company reported ($0.43) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.03 million during the quarter.

AIM ImmunoTech Stock Performance

AIM ImmunoTech stock traded up $0.01 during mid-day trading on Friday, reaching $0.29. 1,026,273 shares of the stock traded hands, compared to its average volume of 1,203,801. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.01. AIM ImmunoTech has a 12-month low of $0.21 and a 12-month high of $2.98. The stock has a market capitalization of $4.16 million, a PE ratio of -0.04 and a beta of 1.20. The business’s 50-day moving average is $0.35 and its 200-day moving average is $0.60.

Institutional Trading of AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Corient Private Wealth LLC acquired a new stake in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned 1.31% of AIM ImmunoTech at the end of the most recent reporting period. 12.02% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets reduced their target price on AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $9.00.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.